Teva Pharmaceutical reported a Q1 net loss of $139m, missing profit estimates, while revenue increased 4% to $3.82bn.
Teva Pharmaceutical Industries missed Q1 profit estimates, reporting a net loss of $139m instead of the expected $51m profit. Revenue, however, increased by 4% to $3.82bn, driven by growth in sales of generic and branded drugs, including those for migraines and Huntington's disease. The company's free cash flow at the end of Q1 was $32m, and its debt amounted to $19.6bn. Teva reaffirmed its annual outlook for 2024.
May 08, 2024
5 Articles